ID   SW1990-GZ
AC   CVCL_ZW95
SY   SW1990/gemcitabine; SW1990-gemcitabine
DR   cancercelllines; CVCL_ZW95
DR   Wikidata; Q102114953
RX   PubMed=31452783;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:175901; Gemcitabine (Gemzar).
CC   Sequence variation: Mutation; HGNC; 27310; FLCN; Simple; p.Gln533Ter (c.1597C>T); ClinVar=VCV000096480; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro191del (c.569_571CTC[1]) (c.572_574delCTC); ClinVar=VCV000458551; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: In situ; Pancreas; UBERON=UBERON_0001264.
DI   NCIt; C8294; Pancreatic adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1723 ! SW1990
SX   Male
AG   56Y
CA   Cancer cell line
DT   Created: 29-10-20; Last updated: 05-10-23; Version: 6
//
RX   PubMed=31452783; DOI=10.3892/ol.2019.10627;
RA   Yu Y., Ding F., Gao M., Jia Y.-F., Ren L.;
RT   "Establishment and characterization of the gemcitabine-resistant human
RT   pancreatic cancer cell line SW1990/gemcitabine.";
RL   Oncol. Lett. 18:3065-3071(2019).
//